Deep Learning: Automated PD-L1 Tumor Cell Scoring of Resected NSCLC, New Webinar Hosted by Xtalks

PD-L1 expression measured by immunohistochemistry helps identify non-small cell lung cancer (NSCLC) patients that may respond to anti-PD-1/PD-L1 immunotherapies.

Xtalks Life Science Webinars

In this live webinar, Nicolas Brieu, Ph.D., Senior Research Scientist at Definiens will present a novel deep learning solution for the automated scoring of PD-L1+ tumor cells (TC) in whole slide images of resected NSCLC.

A convolutional neural network (CNN) was used for the fine-grained classification of tissue regions into three classes: (1) regions of membrane-positive epithelial tumor cells [TC(+)], (2) regions of membrane-negative epithelial tumor cells [TC(-)], and (3) other regions that could wrongly influence scoring, i.e. macrophages, positive and negative lymphocytes, stroma and/or necrosis. The TC score was calculated as the ratio of the area of the classified TC(+) region to the sum of the areas of the classified TC(-) and TC(+) regions.

Two sets of ~225k training and ~30k testing patches (128×128 pixels) were created from manual partial annotations from (N=22) train and (N=12) test slides (Ventana-SP263). Training a fully convolutional network yielded maximum accuracy of 0.89 on test patches. The trained network was applied on (N=433) unseen confirmation slides, and the TC score calculated for each slide based on the classified TC(+) and TC(-) regions. A non-linear gamma mapping to the manual TC scores by a trained pathologist was then estimated to maximize Overall Percent Agreement (OPA) at ≥25% criterion using two-fold cross-validation.

Evaluation against pathologist scoring on the confirmation slides yielded higher Overall (OPA), Negative (NPA) and Positive (PPA) Percent Agreement values at ≥25% criterion, higher Lin’s correlation and lower mean absolute error than a baseline approach relying on a heuristic detection of individual epithelium cells [ESMO-2017-103P]. Scoring by a second pathologist was available on a subset (N=170) of the confirmation slides. Average and standard deviation results on this subset confirm the above observations and suggest that the approach is getting close to inter-pathologist variability.

Join this webinar on Thursday, July 26, 2018 (2 live broadcasts) to learn how using deep learning to identify PD-L1 positive and negative tumor cell regions enables the automated scoring of PD-L1 TCs at the ≥25% expression level in resected NSCLC. These findings should be confirmed with additional tumor sets.

For more information about this complimentary event visit: Deep Learning: Automated PD-L1 Tumor Cell Scoring of Resected NSCLC.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food, and medical device community. Every year thousands of industry practitioners (from life science, food, and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends, and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar

Contact:

Nima Rajan

Tel: +1 (416) 977-6555 ext 352

Email: nrajan@xtalks.com

Source: Xtalks


Categories: Pharmaceuticals and Biotech

Tags: Biomarkers, Cell Scoring, Clinical Trials, Deep Learning, Definiens, Immunotherapy, Laboratory Technology, Medical Device, Non-Small Cell Lung Cancer, NSCLC, Xtalks


Additional Images

Additional Links

About Xtalks

View Website

Xtalks is a leading provider of educational webinars to the global life science, food and medical device community.